1. Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017 Published: May 2017 Single User PDF: US$ 3995 Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any.sales@reportsandreports.com 1 © ReportsnReports.com / Contact sales@reportsandreports.com

2. Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017 Toxicology Cluster Chemotherapy Market Pipeline Overview in 2017 report provides an overview of the toxicology pipeline landscape. The Toxicology Cluster Pipeline Chemotherapy Market Review report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting, Chemotherapy Induced Neutropenia, Chemotherapy Induced Anemia, Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects.Toxicology Cluster Pipeline Chemotherapy Market Review report Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. There are a total of 28 products in development for this indication, by 20 companies. Access Complete Report at: http://www.reportsnreports.com/reports/1001383-toxicology-cluster- chemotherapy-related-toxicity-drug-development-pipeline-review-2017.html.http://www.reportsnreports.com/reports/1001383-toxicology-cluster- chemotherapy-related-toxicity-drug-development-pipeline-review-2017.html Offers from 10th May 2017 to 2nd June 2017 All reports priced >=1,000 – 20% Discount – Single User ; 25% Discount – Global Site License. Buy 2 Reports Get 1 Report Free Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. sales@reportsandreports.com 2 © ReportsnReports.com / Contact sales@reportsandreports.com

3. Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017 Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. There are a total of 41 products in development for this indication, by 31 companies and one academic institution. Chemotherapy-induced anemia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions and/or depression associated with anemia. There are a total of 16 products in development for this indication, by 14 companies. Chemotherapy-induced peripheral neuropathy (CIPN) is a further potential side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. There are a total of 41 products in development for this indication, by 34 companies and four academic institutions. Inquire for Discount http://www.reportsnreports.com/contacts/discount.aspx?name=1001383.http://www.reportsnreports.com/contacts/discount.aspx?name=1001383 Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. sales@reportsandreports.com 3© ReportsnReports.com / Contact sales@reportsandreports.com

4. Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017 Key Companies Operating in this Pipeline include: Helsinn, Luxena Pharmaceuticals, Aphios, Nemus Bioscience and Tesaro, Bolder Biotechnology, USV, Apotex, Biocon, Biogenomics, Generon and Pfizer, Chong Kun Dang and Tolero Pharmaceuticals, Apexian Pharmaceuticals, Celgene and Metys Pharmaceuticals. The dominant molecular targets vary across each of the four pipelines. In CINV and CIPN, there is a relatively diverse range of targets which are being studied. The 5-hydroxytryptamine receptor 3 and substance P receptors are most commonly being studied in CINV, as are the cannabinoid receptors 1 and 2. There is some overlap between this and the CIPN pipeline, with cannabinoid receptors being present amongst the relatively diverse range of targets in development, although with the glutamate ionotropic receptor NMDA-type being the most-frequently selected target. In chemotherapy-induced neutropenia, on the other hand, the granulocyte colony stimulating factor receptor is overwhelmingly the target of choice, accounting for virtually the entire pipeline. Similarly, the erythropoietin receptor makes up the majority of the chemotherapy-induced anemia pipeline. This reflects the relatively focused nature of R&D within these two indications. Buy a Copy of Report @ http://www.reportsnreports.com/purchase.aspx?name=1001383.http://www.reportsnreports.com/purchase.aspx?name=1001383 Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. sales@reportsandreports.com 4© ReportsnReports.com / Contact sales@reportsandreports.com

5. Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017 Scope of the Report Which companies are the most active within the pipeline for toxicology therapeutics? Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? What are the most important R&D milestones and data publications to have happened in the field of toxicology therapeutics? Buy a Copy of Report @ http://www.reportsnreports.com/purchase.aspx?name=1001383.http://www.reportsnreports.com/purchase.aspx?name=1001383 Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. sales@reportsandreports.com 5 © ReportsnReports.com / Contact sales@reportsandreports.com5

6. Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017 List of Tables Number of Products under Development for Chemotherapy Induced Nausea and Vomiting Number of Products under Development by Companies, Chemotherapy Induced Nausea and Vomiting Products under Development by Companies, Chemotherapy Induced Nausea and Vomiting Number of Products under Development for Chemotherapy Induced Neutropenia Number of Products under Development by Companies, Chemotherapy Induced Neutropenia Number of Products under Development by Universities/Institutes, Chemotherapy Induced Neutropenia Products under Development by Companies, Chemotherapy Induced Neutropenia Products under Development by Universities/Institutes, Chemotherapy Induced Neutropenia Number of Products under Development for Chemotherapy Induced Anemia Sample for the Report @ http://www.reportsnreports.com/contacts/requestsample.aspx?name=1001383. http://www.reportsnreports.com/contacts/requestsample.aspx?name=1001383 Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. sales@reportsandreports.com 6 © ReportsnReports.com / Contact sales@reportsandreports.com6

7. About ReportsnReports ReportsnReports.comReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Contact: Ritesh Tiwari Maharashtra, India. Tel: +1-888-391-5441 sales@reportsnreports.com 7© ReportsnReports.com / Contact sales@reportsandreports.com